The United States Preventive Services Task Force released a statement that prostate-specific antigen-based screening for prostate cancer should be avoided in men aged 70 years and older. READ MORE
A cost-effectiveness analysis presented at the 2018 Genitourinary Cancers Symposium examined the use of a hydrogel rectal spacer in patients with prostate cancer undergoing intensity-modulated radiation therapy.
The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the need for further therapy, and is cost effective.
A study to be presented at the 2018 ASCO Genitourinary Cancers Symposium applied the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate and enzalutamide in advanced prostate cancer.
A clinical pathway for patients with prostate cancer patients improved the implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects.